GMRE:NYE-Global Medical REIT Inc (USD)

COMMON STOCK | REIT - Healthcare Facilities |

Last Closing

USD 9.64

Change

-0.19 (-1.93)%

Market Cap

N/A

Volume

0.24M

Analyst Target

USD 14.79
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for REIT - Healthcare Facilities

Symbol Name Price(Change) Market Cap
WELL Welltower Inc

-0.55 (-0.43%)

USD 77.48B
VTR Ventas Inc

-0.65 (-1.02%)

USD 26.47B
DOC Healthpeak Properties Inc

-0.33 (-1.46%)

USD 15.80B
CTRE CareTrust REIT Inc.

-0.18 (-0.58%)

USD 4.74B
AHR American Healthcare REIT, Inc.

-0.30 (-1.18%)

USD 3.88B
NHI National Health Investors Inc

-0.62 (-0.75%)

USD 3.65B
LTC LTC Properties Inc

-0.39 (-1.07%)

USD 1.60B
UHT Universal Health Realty Income..

-0.84 (-1.86%)

USD 0.63B
CHCT Community Healthcare Trust Inc

-0.35 (-1.96%)

USD 0.47B
GMRE-PA Global Medical REIT Inc

+0.19 (+0.74%)

USD 0.41B

ETFs Containing GMRE

KBWY Invesco KBW Premium Yield.. 5.13 % 0.35 %

-0.10 (0%)

USD 0.25B
SDEF 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (REIT - Healthcare Facilities) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.15% 14% F 13% F
Dividend Return 5.68% 79% B- 83% B
Total Return -7.48% 14% F 15% F
Trailing 12 Months  
Capital Gain 10.55% 36% F 36% F
Dividend Return 9.63% 93% A 90% A-
Total Return 20.18% 36% F 45% F
Trailing 5 Years  
Capital Gain -17.61% 46% F 24% F
Dividend Return 35.30% 100% F 88% B+
Total Return 17.69% 54% F 42% F
Average Annual (5 Year Horizon)  
Capital Gain -3.26% N/A N/A 22% F
Dividend Return 3.48% N/A N/A 42% F
Total Return 6.74% N/A N/A 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 25.05% N/A N/A 41% F
Risk Adjusted Return 13.89% N/A N/A 34% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:

There is nothing we particularly dislike